DOCSLIB.ORG

Anti-OX40 Antibody Directly Enhances the Function of Tumor-Reactive Cd8þ T Cells and Synergizes with Pi3kb Inhibition in PTEN Loss Melanoma Weiyi Peng1, Leila J

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Anti-OX40 Antibody Directly Enhances the Function of Tumor-Reactive Cd8þ T Cells and Synergizes with Pi3kb Inhibition in PTEN Loss Melanoma Weiyi Peng1, Leila J Published OnlineFirst August 1, 2019; DOI: 10.1158/1078-0432.CCR-19-1259 Translational Cancer Mechanisms and Therapy Clinical Cancer Research Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8þ T Cells and Synergizes with PI3Kb Inhibition in PTEN Loss Melanoma Weiyi Peng1, Leila J. Williams1, Chunyu Xu1, Brenda Melendez1, Jodi A. McKenzie1, Yuan Chen1, Heather L. Jackson2, Kui S. Voo3, Rina M. Mbofung1, Sara Elizabeth Leahey1, Jian Wang4, Gregory Lizee1, Hussein A. Tawbi1, Michael A. Davies1, Axel Hoos2, James Smothers2, Roopa Srinivasan2, Elaine M. Paul2, Niranjan Yanamandra2, and Patrick Hwu1 Abstract Purpose: OX40 agonist–based combinations are emerging activation of OX40 signaling enhanced their cytotoxic as a novel avenue to improve the effectiveness of cancer function. OX40 agonist antibody improved the antitumor þ immunotherapy. To better guide its clinical development, we activity of CD8 T cells and the generation of tumor- characterized the role of the OX40 pathway in tumor-reactive specific T-cell memory in vivo.Furthermore,combining immune cells. We also evaluated combining OX40 agonists anti-OX40 with GSK2636771, a PI3Kb-selective inhibitor, with targeted therapy to combat resistance to cancer immu- delayed tumor growth and extended the survival of mice notherapy. with PTEN-null melanomas. This combination treatment Experimental Design: We utilized patient-derived tumor- did not increase the number of TILs, but it instead þ infiltrating lymphocytes (TILs) and multiple preclinical mod- significantly enhanced proliferation of CD8 TILs and els to determine the direct effect of anti-OX40 agonistic anti- elevated the serum levels of CCL4, CXCL10, and IFNg, þ bodies on tumor-reactive CD8 T cells. We also evaluated the which are mainly produced by memory and/or effector T antitumor activity of an anti-OX40 antibody plus PI3Kb cells. inhibition in a transgenic murine melanoma model (Braf Conclusions: These results highlight a critical role of mutant, PTEN null), which spontaneously develops immu- OX40 activation in potentiating the effector function of þ notherapy-resistant melanomas. tumor-reactive CD8 T cells and suggest further evaluation Results: We observed elevated expression of OX40 in of OX40 agonist–based combinations in patients with þ tumor-reactive CD8 TILs upon encountering tumors; immune-resistant tumors. 1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2Oncology R&D, Immuno-Oncology Introduction 3 and Combinations RU, GlaxoSmithKline, Collegeville, Pennsylvania. Depart- Several immunomodulatory agents that target T-cell coinhibi- ment of Oncology Research for Biologics and Immunotherapy Translation Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas. tory receptors, such as PD-1 and CTLA-4, have been developed to – 4Department of Biostatistics, The University of Texas MD Anderson Cancer boost T-cell mediated antitumor immune responses in patients Center, Houston, Texas. with cancer. These immunotherapies have demonstrated durable fi Note: Supplementary data for this article are available at Clinical Cancer clinical bene t in many types of cancer, and immune checkpoint Research Online (http://clincancerres.aacrjournals.org/). blockade has become a standard first-line treatment in multiple solid cancers, including melanoma, lung cancer, bladder cancer, Current address for W. Peng and C. Xu: Department of Biology and Biochemistry, University of Houston, Houston, Texas; current address for J.A. McKenzie, Eisai and kidney cancer (1, 2). This new clinical paradigm has shifted Inc., Woodcliff Lake, New Jersey; and current address for R.M. Mbofung, Merck research efforts in tumor immunology to prioritize the identifi- Research Laboratories, Palo Alto, California. cation of additional immunoregulatory targets and rational com- Corresponding Authors: Patrick Hwu, The University of Texas MD Anderson binatorial treatments to further increase the rate of potent and Cancer Center, 1515 Holcombe Blvd Unit 421, Houston, TX 77030. Phone: 713- durable antitumor immune responses. 792-4906; Fax: 713-745-1046; E-mail: [email protected]; Niranjan T-cell activation is tightly regulated by two sets of signals via T- Yanamandra, Immuno-Oncology and Combinations RU, GlaxoSmithKline, cell receptors (TCRs) and T-cell cosignaling receptors. Positive 1250 s, Collegeville Rd, Collegeville, PA 19426. Phone: 610-917-5123; E-mail: (costimulatory) and negative (coinhibitory) signals from T-cell [email protected]; and Weiyi Peng, The University of Houston, cosignaling receptors direct T-cell function in response to TCR 3517 Cullen Blvd, Houston, TX 77204. Phone: 713-743-6941; Fax: 713-743-3415; E-mail: [email protected] stimulation. Several studies have demonstrated that activating T- cell costimulatory receptors, such as OX40 and 4-1BB, can facil- Clin Cancer Res 2019;XX:XX–XX itate T-cell–mediated antitumor immunity (3, 4). Moreover, doi: 10.1158/1078-0432.CCR-19-1259 disrupting T-cell coinhibitory signaling pathways, such as PD-1 Ó2019 American Association for Cancer Research. and CTLA-4, has been reported to reinvigorate tumor-reactive T www.aacrjournals.org OF1 Downloaded from clincancerres.aacrjournals.org on September 26, 2021. © 2019 American Association for Cancer Research. Published OnlineFirst August 1, 2019; DOI: 10.1158/1078-0432.CCR-19-1259 Peng et al. was generated in our previous study (10). All tumor cell lines were Translational Relevance maintained in RPMI1640 complete medium supplemented with Cancer immunotherapy is revolutionizing cancer treat- 10% heat-inactivated FBS (Atlanta Biologicals) and Normocin ment. However, most patients still fail to respond to currently (InvivoGen). TIL cell lines were maintained in RPMI1640 with available immunomodulatory agents. Thus, there remains a 10% human type AB Serum (GEMINI), 3,000 IU/mL IL2 (Pro- critical need to identify novel immunoregulatory targets and metheus Laboratories), and normocin. Cells were routinely mon- rational combinatorial strategies to induce robust and durable itored for Mycoplasma contamination by using the MycoAlert Kit antitumor immune responses. Here, we used patient samples (Lonza). Short tandem repeat profiling was used to confirm the and clinically relevant animal models to evaluate the immu- identity of patient-derived cell lines. The maximum length of time nological and antitumor effects of OX40 agonist–based of in vitro cell culture between thawing and use in the described immunotherapy. Our results add to the growing body of experiments was 2 weeks. evidence that OX40 agonists can boost antitumor immune C57BL/6 mice and C57BL/6 albino mice were purchased responses by modulating T-cell effector function and tumor- from Charles River Frederick Research Model Facility. Tyr:CreER; lox/lox V600E/þ specific memory. Our results also identify a novel therapeutic PTEN ; BRAF (BP) mice bred onto a C57BL/6 back- strategy of combining OX40 agonist antibodies with targeted ground were kindly provided by Dr. Bosenberg (Yale University therapy in patients with cancer, particularly those with tumors School of Medicine, New Haven, CT). Pmel-1 TCR/Thy1.1 mice with loss of the tumor suppressor PTEN. were from in-house breeding colonies. All mice were maintained in a specific pathogen-free barrier facility at MDACC. All studies were conducted in accordance with the MDACC and GlaxoS- mithKline (GSK) Policy on the Care, Welfare, and Treatment of cells and stem tumor development in patients with a variety of Laboratory Animals. All animal experiment protocols were tumors (5). However, a durable and effective antitumor immune reviewed by the Institutional Animal Care and Use Committee response only can be achieved in a small percentage of patients either at GSK or at MDACC, the institution where the work was with cancer treated with immune checkpoint blockade (ICB; performed. ref. 6). One mechanism of primary resistance to ICB is insufficient tumor-reactive T cells in patients with nonimmunogenic Caspase-3–based T-cell killing assay tumors (7). Under the notion that activation of T-cell costimu- Patient-derived tumor cells were labeled with DDAO Dye latory signaling pathways can augment the generation of effector (Thermo Fisher Scientific) according to the manufacturer's and memory T cells (8), more studies are focused on targeting instructions. Peripheral blood mononuclear cells (PBMCs) from T-cell costimulatory receptors to overcome primary resistance to healthy donors were isolated from buffy coats (Gulf Coast ICB therapy in patients with cancer. One such prominent T-cell Regional Blood Center) and irradiated with 5,000 rad of gamma costimulatory molecule is OX40. Indeed, early phase clinical radiation. Irradiated PBMCs were washed with PBS and then trials evaluating agonist antibodies targeting the OX40 pathway incubated with 10 mg/mL full length or Fc-fragment deleted alone or in combination with ICB in patients with cancer are anti-human OX40 (GSK3174998, GSK) at 37C for 1 hour. ongoing, such as NCT02221960 (formerly of MedImmune), Antibody-pulsed PBMCs were mixed with DDAO-labeled tumor NCT02528357 (GlaxoSmithKline), and NCT02554812 (Pfizer). cells and autologous TILs at 37C for an additional 3 hours. The While these trials have begun, an improved understanding of the ratio of T cells to PBMCs used in this assay was 1:1. To impact of OX40 activation on immune effector cells may help to evaluate the effect of the activation of the OX40 pathway in þ optimize
Load more

Recommended publications
  • Review of Dendritic Cells, Their Role in Clinical Immunology, and Distribution in Various Animal Species
    International Journal of Molecular Sciences Review Review of Dendritic Cells, Their Role in Clinical Immunology, and Distribution in Various Animal Species Mohammed Yusuf Zanna 1 , Abd Rahaman Yasmin 1,2,* , Abdul Rahman Omar 2,3 , Siti Suri Arshad 3, Abdul Razak Mariatulqabtiah 2,4 , Saulol Hamid Nur-Fazila 3 and Md Isa Nur Mahiza 3 1 Department of Veterinary Laboratory Diagnosis, Faculty of Veterinary Medicine, Universiti Putra Malaysia (UPM), Serdang 43400, Selangor, Malaysia; [email protected] 2 Laboratory of Vaccines and Biomolecules, Institute of Bioscience, Universiti Putra Malaysia (UPM), Serdang 43400, Selangor, Malaysia; [email protected] (A.R.O.); [email protected] (A.R.M.) 3 Department of Veterinary Pathology and Microbiology, Faculty of Veterinary Medicine, Universiti Putra Malaysia (UPM), Serdang 43400, Selangor, Malaysia; [email protected] (S.S.A.); [email protected] (S.H.N.-F.); [email protected] (M.I.N.M.) 4 Department of Cell and Molecular Biology, Faculty of Biotechnology and Biomolecular Science, Universiti Putra Malaysia (UPM), Serdang 43400, Selangor, Malaysia * Correspondence: [email protected]; Tel.: +603-8609-3473 or +601-7353-7341 Abstract: Dendritic cells (DCs) are cells derived from the hematopoietic stem cells (HSCs) of the bone marrow and form a widely distributed cellular system throughout the body. They are the most effi- cient, potent, and professional antigen-presenting cells (APCs) of the immune system, inducing and dispersing a primary immune response by the activation of naïve T-cells, and playing an important role in the induction and maintenance of immune tolerance under homeostatic conditions. Thus, this Citation: Zanna, M.Y.; Yasmin, A.R.; review has elucidated the general aspects of DCs as well as the current dynamic perspectives and Omar, A.R.; Arshad, S.S.; distribution of DCs in humans and in various species of animals that includes mouse, rat, birds, dog, Mariatulqabtiah, A.R.; Nur-Fazila, cat, horse, cattle, sheep, pig, and non-human primates.
    [Show full text]
  • Acting on the CCR1 Receptor Mediates Neutrophil Migration in Immune Inflammation Via Sequential ␣ Release of TNF- and LTB4 Cleber D
    MIP-1␣[CCL3] acting on the CCR1 receptor mediates neutrophil migration in immune inflammation via sequential ␣ release of TNF- and LTB4 Cleber D. L. Ramos,* Claudio Canetti,*,† Janeusa T. Souto,‡,§ Joa˜ o S. Silva,‡ Cory M. Hogaboam,¶ Sergio H. Ferreira,* and Fernando Q. Cunha*,1 Departments of *Pharmacology and ‡Biochemistry and Immunology, School of Medicine of Ribeira˜o Preto, University of Sa˜o Paulo, Brazil; §Department of Microbiology and Parasitology, Federal University of Rio Grande do Norte, Natal, RN, Brazil; and †Division of Pulmonary & Critical Care Medicine and ¶Department of Pathology, University of Michigan, Ann Arbor Abstract: In the present study, we investigated nists might have a therapeutic potential. J. Leukoc. the involvement of macrophage-inflammatory pro- Biol. 78: 167–177; 2005. tein-1␣ (MIP-1␣)[CC chemokine ligand 3 (CCL3)], MIP-1␤[CCL4], regulated on activation, normal Key Words: chemokines ⅐ chemokine receptors ⅐ chemotaxis T expressed and secreted (RANTES)[CCL5], and CC chemokine receptors (CCRs) on neutrophil mi- gration in murine immune inflammation. Previ- INTRODUCTION ously, we showed that ovalbumin (OVA)-triggered neutrophil migration in immunized mice depends on the sequential release of tumor necrosis factor Neutrophil migration is a complex process, which results ␣ ␣ mainly from the release of neutrophil chemotactic factors by (TNF- ) and leukotriene B4 (LTB4). Herein, we show increased mRNA expression for MIP- resident cells, inducing rolling and adhesion of neutrophils on 1␣[CCL3], MIP-1␤[CCL4], RANTES[CCL5], and endothelial cells, followed by their transmigration to the ex- travascular space [1, 2]. Apart from its importance in host CCR1 in peritoneal cells harvested from OVA-chal- defense, the migration of neutrophils to the inflammatory site lenged, immunized mice, as well as MIP-1␣[CCL3] is, at least in part, responsible for tissue damage observed in and RANTES[CCL5] but not MIP-1␤[CCL4] proteins several inflammatory diseases such as rheumatoid arthritis, in the peritoneal exudates.
    [Show full text]
  • Bioinformatics Identification of CCL8/21 As Potential Prognostic
    Bioscience Reports (2020) 40 BSR20202042 https://doi.org/10.1042/BSR20202042 Research Article Bioinformatics identification of CCL8/21 as potential prognostic biomarkers in breast cancer microenvironment 1,* 2,* 3 4 5 1 Bowen Chen , Shuyuan Zhang ,QiuyuLi, Shiting Wu ,HanHe and Jinbo Huang Downloaded from http://portlandpress.com/bioscirep/article-pdf/40/11/BSR20202042/897847/bsr-2020-2042.pdf by guest on 28 September 2021 1Department of Breast Disease, Maoming People’s Hospital, Maoming 525000, China; 2Department of Clinical Laboratory, Maoming People’s Hospital, Maoming 525000, China; 3Department of Emergency, Maoming People’s Hospital, Maoming 525000, China; 4Department of Oncology, Maoming People’s Hospital, Maoming 525000, China; 5Department of Medical Imaging, Maoming People’s Hospital, Maoming 525000, China Correspondence: Shuyuan Zhang ([email protected]) Background: Breast cancer (BC) is the most common malignancy among females world- wide. The tumor microenvironment usually prevents effective lymphocyte activation and infiltration, and suppresses infiltrating effector cells, leading to a failure of the host toreject the tumor. CC chemokines play a significant role in inflammation and infection. Methods: In our study, we analyzed the expression and survival data of CC chemokines in patients with BC using several bioinformatics analyses tools. Results: The mRNA expression of CCL2/3/4/5/7/8/11/17/19/20/22 was remark- ably increased while CCL14/21/23/28 was significantly down-regulated in BC tis- sues compared with normal tissues. Methylation could down-regulate expression of CCL2/5/15/17/19/20/22/23/24/25/26/27 in BC. Low expression of CCL3/4/23 was found to be associated with drug resistance in BC.
    [Show full text]
  • Association of Chemokine CCL5 and Systemic Malignancies
    J Hum Genet (2008) 53:377–378 DOI 10.1007/s10038-008-0270-6 LETTER TO THE EDITOR Association of chemokine CCL5 and systemic malignancies Shailendra Kapoor Received: 28 January 2008 / Accepted: 8 February 2008 / Published online: 27 March 2008 Ó The Japan Society of Human Genetics and Springer 2008 To the Editor CCL5 levels are also increased in a wide spectrum of The article by Konta et al. (2008) on the relationship other diseases, such as idiopathic inflammatory myopathies between CC chemokine ligand 5 (CCL5) genotype and (Civatte et al. 2005) and chronic gastritis (Ohtani et al. urinary albumin excretion in the nondiabetic Japanese 2004). The recent study by Konta et al. further adds to general population is highly interesting. The study by diseases in which CCL5 plays a major pathogenetic role. Konta et al. adds to the growing array of pathological Further studies are needed to identify potent and safe conditions in which CCL5 plays a major role. Interestingly, inhibitors of CCL5 for better management of these diseases CCL5 has recently been implicated in the etiopathogenesis ranging from breast cancer to nondiabetic albuminuria. of a number of systemic malignancies. For instance, Luboshits et al. (1999), in a recent study, have shown that advanced breast cancers are associated References with increased expression of CCL5. CCL5 has also been shown to be a significant predictor of progression in Aldinucci D, Lorenzon D, Cattaruzza L, Pinto A, Gloghini A, Carbone A, Colombatti A (2008) Expression of CCR5 receptors patients with stage II breast cancer (Hahoshen et al. 2006). on Reed-Sternberg cells and Hodgkin lymphoma cell lines: In another study, tumors that expressed higher levels of involvement of CCL5/Rantes in tumor cell growth and micro- CCL5 were more likely to metastasize in comparison with environmental interactions.
    [Show full text]
  • Platelet-Derived Growth Factor Isoform Expression in Carbon Tetrachloride
    Laboratory Investigation (2008) 88, 1090–1100 & 2008 USCAP, Inc All rights reserved 0023-6837/08 $30.00 Platelet-derived growth factor isoform expression in carbon tetrachloride-induced chronic liver injury Erawan Borkham-Kamphorst1, Evgenia Kovalenko1, Claudia RC van Roeyen2, Nikolaus Gassler3, Michael Bomble1, Tammo Ostendorf 2,Ju¨rgen Floege2, Axel M Gressner1 and Ralf Weiskirchen1 Platelet-derived growth factor (PDGF) has an essential role in liver fibrogenesis, as PDGF-B and -D both act as potent mitogens on culture-activated hepatic stellate cells (HSCs). Induction of PDGF receptor type-b (PDGFRb) in HSC is well documented in single-dose carbon tetrachloride (CCl4)-induced acute liver injury. Of the newly discovered isoforms PDGF- C and -D, only PDGF-D shows significant upregulation in bile duct ligation (BDL) models. We have now investigated the expression of PDGF isoforms and receptors in chronic liver injury in vivo after long-term CCl4 treatment and demonstrated that isolated hepatocytes have the requisite PDGF signaling pathways, both in the naive state and when isolated from CCl4-treated rats. In vivo, PDGF gene expression showed upregulation of all PDGF isoforms and receptors, with values peaking at 4 weeks and decreasing to near basal levels by 8 and 12 weeks. Interestingly, PDGF-C increased significantly when compared to BDL-models. PDGF-A, PDGF-C and PDGF receptor type-a (PDGFRa) correlated closely with in- flammation and steatosis. Immunohistochemistry revealed expression of PDGF-B, -C and -D in areas corresponding to centrilobular necrosis, inflammation and fibrosis, whereas PDGF-A localized in regenerative hepatocytes. PDGFRb was identified along the fibrotic septa, whereas PDGFRa showed positive staining in fibrotic septa and regenerative hepa- tocytes.
    [Show full text]
  • 5-O-Demethylnobiletin Alleviates Ccl4-Induced Acute Liver Injury by Equilibrating ROS-Mediated Apoptosis and Autophagy Induction
    International Journal of Molecular Sciences Article 5-O-Demethylnobiletin Alleviates CCl4-Induced Acute Liver Injury by Equilibrating ROS-Mediated Apoptosis and Autophagy Induction Sukkum Ngullie Chang 1,2,†, Se Ho Kim 2,3,†, Debasish Kumar Dey 1, Seon Min Park 2, Omaima Nasif 4, Vivek K. Bajpai 5,*, Sun Chul Kang 1, Jintae Lee 3,* and Jae Gyu Park 2,* 1 Department of Biotechnology, Daegu University, Gyeongsan 38453, Korea; [email protected] (S.N.C.); [email protected] (D.K.D.); [email protected] (S.C.K.) 2 Advanced Bio Convergence Center (ABCC), Pohang Technopark Foundation, Pohang 37668, Korea; [email protected] (S.H.K.); [email protected] (S.M.P.) 3 School of Chemical Engineering, Yeungnam University, Gyeongsan 38541, Korea 4 Department of Physiology, College of Medicine, King Saud University (Medical City), King Khalid University Hospital, P.O. Box 2925, Riyadh 11461, Saudi Arabia; [email protected] 5 Department of Energy and Materials Engineering, Dongguk University-Seoul, 30 Pildong-ro 1-gil, Seoul 04620, Korea * Correspondence: [email protected] (V.K.B.); [email protected] (J.T.L.); [email protected] (J.G.P.); Fax: +82-32-872-4046 (V.K.B.); +82-53-810-4631 (J.L.); +82-54-223-2780 (J.G.P.) † Contributed equally to this work. Abstract: Polymethoxyflavanoids (PMFs) have exhibited a vast array of therapeutic biological properties. 5-O-Demethylnobiletin (5-DN) is one such PMF having anti-inflammatory activity, yet its role in hepatoprotection has not been studied before. Results from in vitro study revealed that Citation: Chang, S.N.; Kim, S.H.; 5-DN did not exert a high level of cytotoxicity on HepG2 cells at 40 µM, and it was able to rescue Dey, D.K.; Park, S.M.; Nasif, O.; HepG2 cell death induced by carbon tetrachloride (CCl4).
    [Show full text]
  • The CCL7-CCL2-CCR2 Axis Regulates IL-4 Production in Lungs and Fungal Immunity Wendy A
    The CCL7-CCL2-CCR2 Axis Regulates IL-4 Production in Lungs and Fungal Immunity Wendy A. Szymczak and George S. Deepe, Jr This information is current as J Immunol 2009; 183:1964-1974; Prepublished online 8 July of September 29, 2021. 2009; doi: 10.4049/jimmunol.0901316 http://www.jimmunol.org/content/183/3/1964 Downloaded from References This article cites 57 articles, 33 of which you can access for free at: http://www.jimmunol.org/content/183/3/1964.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 29, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology The CCL7-CCL2-CCR2 Axis Regulates IL-4 Production in Lungs and Fungal Immunity1 Wendy A. Szymczak*† and George S. Deepe, Jr.2*‡ Expression of the chemokine receptor CCR2 can be detrimental or beneficial for infection resolution.
    [Show full text]
  • Stabilin-1 Expression Defines a Subset of Macrophages That Mediate Tissue Homeostasis and Prevent Fibrosis in Chronic Liver Injury
    Stabilin-1 expression defines a subset of macrophages that mediate tissue homeostasis and prevent fibrosis in chronic liver injury Pia Rantakaria,1, Daniel A. Pattenb,1, Joona Valtonena, Marika Karikoskia, Heidi Gerkea, Harriet Dawesb, Juha Laurilaa, Steffen Ohlmeierc, Kati Elimad, Stefan G. Hübschere, Chris J. Westonb, Sirpa Jalkanena, David H. Adamsb, Marko Salmia, and Shishir Shettyb,2 aMediCity Research Laboratory and Department of Medical Microbiology and Immunology, University of Turku, FI-20520, Turku, Finland; bNational Institute for Health Research Birmingham Liver Biomedical Research Unit and Centre for Liver Research, Institute of Immunology and Immunotherapy, Universityof Birmingham, Birmingham B15 2TT, United Kingdom; cProteomics Core Facility, Biocenter Oulu, Faculty of Biochemistry and Molecular Medicine, University of Oulu, FI-90014, Oulu, Finland; dMediCity Research Laboratory, Department of Medical Biochemistry and Genetics, University of Turku, FI-20520, Turku, Finland; and eSchool of Cancer Sciences, University of Birmingham B15 2TT, Birmingham, United Kingdom Edited by Jeffrey W. Pollard, Albert Einstein College of Medicine, Bronx, NY, and accepted by Editorial Board Member Brigid L. Hogan June 17, 2016 (received for review March 29, 2016) Macrophages are key regulators of fibrosis development and reso- Previous studies have demonstrated multiple stabilin-1 ligands, lution. Elucidating the mechanisms by which they mediate this including oxLDL (7), the ECM glycoprotein osteonectin (8), and process is crucial for establishing their therapeutic potential. Here, placental lactogen (9), suggesting that stabilin-1 functions as a we use experimental models of liver fibrosis to show that deficiency homeostatic scavenger receptor. We have previously reported of the scavenger receptor, stabilin-1, exacerbates fibrosis and delays stabilin-1 expression by HSEC, but not by resident liver macro- resolution during the recovery phase.
    [Show full text]
  • Fas/Fasl Mediates NF-Κbp65/PUMA-Modulated
    Tan et al. Cell Death and Disease (2021) 12:474 https://doi.org/10.1038/s41419-021-03749-x Cell Death & Disease ARTICLE Open Access Fas/FasL mediates NF-κBp65/PUMA-modulated hepatocytes apoptosis via autophagy to drive liver fibrosis Siwei Tan 1,2,XianzhiLiu1, Lingjun Chen1, Xiaoqin Wu1,LiTao1,XuemeiPan1,ShuyanTan1, Huiling Liu1,JieJiang1 and Bin Wu 1,2 Abstract Fas/Fas ligand (FasL)-mediated cell apoptosis involves a variety of physiological and pathological processes including chronic hepatic diseases, and hepatocytes apoptosis contributes to the development of liver fibrosis following various causes. However, the mechanism of the Fas/FasL signaling and hepatocytes apoptosis in liver fibrogenesis remains unclear. The Fas/FasL signaling and hepatocytes apoptosis in liver samples from both human sections and mouse models were investigated. NF-κBp65 wild-type mice (p65f/f), hepatocytes specific NF-κBp65 deletion mice (p65Δhepa), p53-upregulated modulator of apoptosis (PUMA) wild-type (PUMA-WT) and PUMA knockout (PUMA-KO) littermate models, and primary hepatic stellate cells (HSCs) were also used. The mechanism underlying Fas/FasL-regulated hepatocytes apoptosis to drive HSCs activation in fibrosis was further analyzed. We found Fas/FasL promoted PUMA- mediated hepatocytes apoptosis via regulating autophagy signaling and NF-κBp65 phosphorylation, while inhibition of autophagy or PUMA deficiency attenuated Fas/FasL-modulated hepatocytes apoptosis and liver fibrosis. Furthermore, NF-κBp65 in hepatocytes repressed PUMA-mediated hepatocytes apoptosis via regulating the Bcl-2 κ fi 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; family, while NF- Bp65 de ciency in hepatocytes promoted PUMA-mediated hepatocytes apoptosis and enhanced apoptosis-linked inflammatory response, which contributed to the activation of HSCs and liver fibrogenesis.
    [Show full text]
  • CCL3L1 and CCL4L1: Variable Gene Copy Number in Adolescents with and Without Human Immunodeficiency Virus Type 1 (HIV-1) Infection
    Genes and Immunity (2007) 8, 224–231 & 2007 Nature Publishing Group All rights reserved 1466-4879/07 $30.00 www.nature.com/gene ORIGINAL ARTICLE CCL3L1 and CCL4L1: variable gene copy number in adolescents with and without human immunodeficiency virus type 1 (HIV-1) infection W Shao1, J Tang2, W Song1, C Wang1,YLi2, CM Wilson2,3 and RA Kaslow1,2 1Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA; 2Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA and 3Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA As members of the chemokine family, macrophage inflammatory protein 1 alpha (MIP-1a) and MIP-1b are unique in that they both consist of non-allelic isoforms encoded by different genes, namely chemokine (C-C motif) ligand 3 (CCL3), CCL4, CCL3- like 1 (CCL3L1) and CCL4L1. The products of these genes and of CCL5 (encoding RANTES, i.e., regulated on activation, normal T expressed and secreted) can block or interfere with human immunodeficiency virus type 1 (HIV-1) infection through competitive binding to chemokine (C-C motif) receptor 5 (CCR5). Our analyses of 411 adolescents confirmed that CCL3 and CCL4 genes occurred invariably as single copies (two per diploid genome), whereas the copy numbers of CCL3L1 and CCL4L1 varied extensively (0–11 and 1–6 copies, respectively). Neither CCL3L1 nor CCL4L1 gene copy number variation showed appreciable impact on susceptibility to or control of HIV-1 infection. Within individuals, linear correlation between CCL3L1 and CCL4L1 copy numbers was moderate regardless of ethnicity (Pearson correlation coefficients ¼ 0.63–0.65, Po0.0001), suggesting that the two loci are not always within the same segmental duplication unit.
    [Show full text]
  • Carbon Tetrachloride-Induced Hepatic Injury Through Formation of Oxidized
    Laboratory Investigation (2013) 93, 218–229 & 2013 USCAP, Inc All rights reserved 0023-6837/13 $32.00 Carbon tetrachloride-induced hepatic injury through formation of oxidized diacylglycerol and activation of the PKC/NF-kB pathway Kentaro Toriumi1, Yosuke Horikoshi1, R Yoshiyuki Osamura1, Yorihiro Yamamoto2, Naoya Nakamura1 and Susumu Takekoshi1,3 Protein kinase C (PKC) participates in signal transduction, and its overactivation is involved in various types of cell injury. PKC depends on diacylglycerol (DAG) for its activation in vivo We have previously reported that DAG peroxides (DAG- O(O)H) activate PKC in vitro more strongly than unoxidized DAG, suggesting that DAG-O(O)H, if generated in vivo under oxidative stress, would act as an aberrant signal transducer. The present study examined whether DAG-O(O)H are formed in carbon tetrachloride (CCl4)-induced acute rat liver injury in association with activation of the PKC/nuclear factor (NF)-kB pathway. A single subcutaneous injection of CCl4 resulted in a marked increase in hepatic DAG-O(O)H content. At the molecular level, immunohistochemistry and subcellular fractionation combined with immunoblotting localized PKCa, bI, bII and d isoforms to cell membranes, while immunoblotting showed phosphorylation of the p65 subunit of NF-kB, and immunoprecipitation using isoform-specific anti-PKC antibodies revealed specific association of PKCa and p65. In addi- tion, expression of tumor necrosis factor a (TNFa) and neutrophil invasion increased in the CCl4-treated rats. Furthermore, we demonstrated that Vitamin E, one of the most important natural antioxidants that suppresses peroxidation of membrane lipids, significantly inhibited the CCl4-induced increase in hepatic DAG-O(O)H content and TNFa expression as well as phosphorylation of PKCa and p65.
    [Show full text]
  • Monocyte/Macrophage-Derived CCL11 Inflammatory + CCR2 High
    Colonic Eosinophilic Inflammation in Experimental Colitis Is Mediated by Ly6C high CCR2+ Inflammatory Monocyte/Macrophage-Derived CCL11 This information is current as of October 1, 2021. Amanda Waddell, Richard Ahrens, Kris Steinbrecher, Burke Donovan, Marc E. Rothenberg, Ariel Munitz and Simon P. Hogan J Immunol 2011; 186:5993-6003; Prepublished online 15 April 2011; Downloaded from doi: 10.4049/jimmunol.1003844 http://www.jimmunol.org/content/186/10/5993 Supplementary http://www.jimmunol.org/content/suppl/2011/04/15/jimmunol.100384 http://www.jimmunol.org/ Material 4.DC1 References This article cites 67 articles, 28 of which you can access for free at: http://www.jimmunol.org/content/186/10/5993.full#ref-list-1 Why The JI? Submit online. by guest on October 1, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2011 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Colonic Eosinophilic Inflammation in Experimental Colitis Is Mediated by Ly6Chigh CCR2+ Inflammatory Monocyte/Macrophage-Derived CCL11 Amanda Waddell,* Richard Ahrens,* Kris Steinbrecher,† Burke Donovan,* Marc E.
    [Show full text]